Literature DB >> 2841084

Antihypertensive drugs interacting with alpha- and beta-adrenoceptors. A review of basic pharmacology.

P A van Zwieten1.   

Abstract

Antihypertensive activity can be induced by the following types of drugs: alpha-adrenoceptor antagonists; beta-adrenoceptor antagonists (beta-blockers); and alpha 2-adrenoceptor agonists (in the central nervous system). After a general survey of peripheral and central alpha- and beta-adrenoceptors, including their modern classification and subdivision, attention was paid to the various drugs with antihypertensive activity based upon interaction with various alpha- and beta-adrenoceptors. Of the peripheral alpha-adrenoceptor blockers, only those selective for alpha 1-adrenoceptors are useful antihypertensives. Prazosin and its successors (doxazosin, terazosin, trimazosin) are the best-known examples of such drugs. Their mode of action, and the low incidence and degree of reflex tachycardia, can be satisfactorily explained on the basis of alpha 1-adrenoceptor blockade in the periphery and possibly also in the CNS. Urapidil is a selective alpha 1-adrenoceptor blocker with an additional central component not based upon interaction with alpha-adrenoceptors. With respect to centrally acting alpha 2-adrenoceptor agonists, clonidine, guanfacine and alpha-methyldopa are the prototypes. Their antihypertensive activity is triggered by the stimulation of central alpha 2-adrenoceptors in the brain stem, causing reduced peripheral sympathetic activity and hence a fall in blood pressure and heart rate. Sedation, a common side effect of these drugs, is assumed to be mediated by alpha 2-adrenoceptors at cortical sites. Although beta-adrenoceptor blocking agents (beta-blockers) are widely and successfully used as antihypertensives, their mode of action is still poorly understood, only hypotheses being available at present. However, their side effects can be rationally explained on the basis of beta-adrenoceptor blockade.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841084     DOI: 10.2165/00003495-198800356-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  29 in total

Review 1.  Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-09       Impact factor: 9.546

2.  Overview of alpha 2-adrenoceptor agonists with a central action.

Authors:  P A van Zwieten
Journal:  Am J Cardiol       Date:  1986-03-28       Impact factor: 2.778

Review 3.  Alpha-adrenoceptor subclassification.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1981       Impact factor: 5.545

4.  Characterization of the antihypertensive activity of SK&F 86466, a selective alpha-2 antagonist, in the rat.

Authors:  J M Roesler; J P McCafferty; R M DeMarinis; W D Matthews; J P Hieble
Journal:  J Pharmacol Exp Ther       Date:  1986-01       Impact factor: 4.030

Review 5.  Role of alpha adrenoceptors in hypertension and in antihypertensive drug treatment.

Authors:  P A Van Zwieten; P B Timmermans; P Van Brummelen
Journal:  Am J Med       Date:  1984-10-05       Impact factor: 4.965

6.  [Studies on the effect of urapidil on the central nervous system and various organ functions in animal experiments (author's transl)].

Authors:  W Schoetensack; M Eltze; S Gönne; K P Kley; H G Menge; H Müller
Journal:  Arzneimittelforschung       Date:  1977

7.  Alpha 1-and alpha 2-adrenoceptor mediated vasoconstriction in the forearm of normotensive and hypertensive subjects.

Authors:  K Jie; P van Brummelen; P Vermey; P B Timmermans; P A van Zwieten
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jan-Feb       Impact factor: 3.105

8.  The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade.

Authors:  J W Constantine; W Lebel; R Weeks
Journal:  J Cardiovasc Pharmacol       Date:  1984 Jan-Feb       Impact factor: 3.105

9.  Evidence for a central sympathoexcitatory action of alpha-2 adrenergic antagonists.

Authors:  R B McCall; M R Schuette; S J Humphrey; R A Lahti; C Barsuhn
Journal:  J Pharmacol Exp Ther       Date:  1983-03       Impact factor: 4.030

Review 10.  Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.

Authors:  R A Young; R N Brogden
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

View more
  6 in total

1.  Acute haemodynamic effects of urapidil and nifedipine in hypertensive urgencies and emergencies.

Authors:  F Späh; K D Grosser; G Thieme
Journal:  Drugs       Date:  1990       Impact factor: 9.546

2.  Discriminative stimulus effects of the alpha 2-adrenoceptor antagonist idazoxan.

Authors:  D J Sanger
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Biochemical effects of urapidil on red cell membrane ion transport systems in a population of elderly essential hypertensives.

Authors:  R Antonicelli; E Balducci; G Lipponi; C Lucantoni; R Gaetti; E Paciaroni
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

Review 4.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Gender difference and change of α(1)-adrenoceptors in the distal mesenteric arteries of streptozotocin-induced diabetic rats.

Authors:  Sang-Hyun Park; Jae-Hyon Bahk; Ah-Young Oh; Nam-Su Gil; Jin Huh; Jong-Hwan Lee
Journal:  Korean J Anesthesiol       Date:  2011-11-23

Review 6.  Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates.

Authors:  Monika Marcinkowska; Joanna Śniecikowska; Nikola Fajkis; Paweł Paśko; Weronika Franczyk; Marcin Kołaczkowski
Journal:  CNS Drugs       Date:  2020-03       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.